William Blair analyst Matt Phipps reiterated a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report) today. The company’s shares ...
Granite 3.2 - small AI models offering reasoning, vision, and guardrail capabilities with a developer friendly license Updated Granite time series models that offer long-range forecasting with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback